Emerging Treatments for Managing mCRPC Patients

As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your undertaking of this E-Learning module allow you to discuss increased insight into prostate cancer biology and a rationale for manipulating with blockade of underlining signaling pathway in the development of novel targeted treatments? (1-not at all; 5-yes absolutely)

2. Did your undertaking of this E-Learning module allow you to review a mechanism of action and clinical data on emerging therapies in the management of patients with metastatic castration resistant prostate cancer (mCRPC)? (1-not at all; 5-yes absolutely)

3. Did your undertaking of this E-Learning module allow you to provide an update on the progress made in designing novel treatments for patients with mCRPC and critically discuss how to use them in the clinical context? (1-not at all; 5-yes absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-not at all; 5-yes absolutely)

5. How would you rate the interactivity level offered in the E-Learning material? (1-not at all; 5-yes absolutely)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-yes absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-yes absolutely)

8. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: